Related Experiment Video
Updated: Oct 13, 2025

10:03
Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
1.9K
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
1Barbara Davis Center for Diabetes, Aurora, CO viral.shah@cuanschutz.edu.
The New England Journal of Medicine
|November 10, 2021
Abstract
No abstract available in PubMed .

